{"id":745446,"date":"2017-11-30T07:00:00","date_gmt":"2017-11-30T07:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-and-updated-data-for-mercks-keytruda-pembrolizumab-and-updated-data-on-lynparza-olaparib-in-multiple-breast-cancer-subtypes-to-be-presented-at-the-2017-san-antonio-breast\/"},"modified":"2025-11-07T01:26:07","modified_gmt":"2025-11-07T06:26:07","slug":"new-and-updated-data-for-mercks-keytruda-pembrolizumab-and-updated-data-on-lynparza-olaparib-in-multiple-breast-cancer-subtypes-to-be-presented-at-the-2017-san-antonio-breast","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-and-updated-data-for-mercks-keytruda-pembrolizumab-and-updated-data-on-lynparza-olaparib-in-multiple-breast-cancer-subtypes-to-be-presented-at-the-2017-san-antonio-breast\/","title":{"rendered":"New and Updated Data for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) and Updated Data on LYNPARZA\u00ae (olaparib) in Multiple Breast Cancer Subtypes to Be Presented at the 2017 San Antonio Breast Cancer Symposium (SABCS)"},"content":{"rendered":"<p class=\"bwalignc\">        Efficacy Data from Phase 2 KEYNOTE-086 Trial, Cohort B, for        KEYTRUDA Monotherapy in Patients with Untreated Metastatic        Triple-Negative Breast Cancer to Be Featured in Spotlight Session      <\/p>\n<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that new and updated data from six abstracts<br \/>\n      investigating KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab), the company\u2019s<br \/>\n      anti-PD-1 therapy, as both monotherapy and combination therapy, across a<br \/>\n      range of difficult-to-treat breast cancers, will be presented at the<br \/>\n      2017 San Antonio Breast Cancer Symposium (SABCS), Dec. 5 \u2013 9. In<br \/>\n      addition to the presentation of KEYTRUDA data at SABCS, updated data on<br \/>\n      LYNPARZA<sup>\u00ae<\/sup> (olaparib), the first-in-class poly ADP-ribose<br \/>\n      polymerase (PARP) inhibitor being co-developed and co-commercialized<br \/>\n      with AstraZeneca, will be presented.\n    <\/p>\n<p>\n      KEYTRUDA presentations include a Spotlight Session with findings from<br \/>\n      the phase 2 KEYNOTE-086 trial, Cohort B, investigating KEYTRUDA as a<br \/>\n      monotherapy in previously untreated patients with metastatic<br \/>\n      triple-negative breast cancer (TNBC) whose tumors express PD-L1<br \/>\n      (Abstract #PD6-10). In the combination setting, KEYTRUDA data highlights<br \/>\n      at SABCS include:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Final results from the phase 1b\/2 KEYNOTE-014 (PANACEA) trial<br \/>\n        investigating KEYTRUDA in combination with trastuzumab in<br \/>\n        trastuzumab-resistant HER2-positive metastatic breast cancer (Abstract<br \/>\n        #GS2-06);\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Two new biomarker analyses from the ongoing phase 2 I-SPY 2 trial<br \/>\n        (Abstract #PD6-08, Abstract #PD6-14); and,\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Updated data from the phase 1b\/2 KEYNOTE-150 (ENHANCE-1) trial<br \/>\n        investigating KEYTRUDA (pembrolizumab) in combination<i> <\/i>with<br \/>\n        Eisai Co., Ltd.\u2019s microtubule dynamics inhibitor, eribulin mesylate<br \/>\n        (product name: Halaven<sup>\u00ae<\/sup>, \u201ceribulin\u201d), in patients with<br \/>\n        metastatic TNBC (Abstract #PD6-13).\n      <\/li>\n<\/ul>\n<p>\n      Data investigating LYNPARZA (olaparib) as monotherapy will also be<br \/>\n      presented. Findings include additional data from the pivotal phase 3<br \/>\n      OlympiAD trial investigating LYNPARZA versus chemotherapy in patients<br \/>\n      with HER2-negative metastatic breast cancer and a germline BRCA mutation<br \/>\n      (Abstract #P5-21-12), as well as a subgroup analysis in Asian patients<br \/>\n      (Abstract #P5-21-13).\n    <\/p>\n<p>\n      \u201cWe have seen significant therapeutic advances over the years in the<br \/>\n      field of breast cancer; however, there remains significant unmet medical<br \/>\n      need, particularly in certain categories of the disease,\u201d said Dr. Roy<br \/>\n      Baynes, senior vice president and head of global clinical development,<br \/>\n      chief medical officer, Merck Research Laboratories. \u201cThrough our<br \/>\n      comprehensive clinical program studying KEYTRUDA, as well as LYNPARZA,<br \/>\n      we hope to bring additional therapeutic benefit to breast cancer<br \/>\n      patients.\u201d\n    <\/p>\n<p>\n      A select list of the KEYTRUDA-related abstracts accepted for<br \/>\n      presentation at SABCS are included below. For a complete list of<br \/>\n      KEYTRUDA and LYNPARZA abstract titles, please visit the SABCS <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sabcs.org%2F2017-SABCS&amp;esheet=51723054&amp;newsitemid=20171130005484&amp;lan=en-US&amp;anchor=website&amp;index=1&amp;md5=34f8f2c52632710efc73ef7dcd1364d7\" rel=\"nofollow\">website<\/a>.\n    <\/p>\n<p>\n      <b>KEYTRUDA-Related Data at SABCS<\/b>\n    <\/p>\n<p>\n      <span class=\"bwuline\">Monotherapy Abstracts:<\/span>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract #PD6-10 Spotlight Session: KEYNOTE-086 cohort B:<br \/>\n        Pembrolizumab monotherapy for PD-L1-positive, previously untreated,<br \/>\n        metastatic triple-negative breast cancer (mTNBC). Adams S. Thursday,<br \/>\n        Dec. 7. 5:00 p.m. \u2013 7:00 p.m. CT. Location: Stars at Night Ballroom 3<br \/>\n        &amp; 4.<\/i>\n      <\/li>\n<\/ul>\n<p>\n      <span class=\"bwuline\">Combination Abstracts:<\/span>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract #GS2-06 Oral Presentation: Phase Ib\/II study evaluating<br \/>\n        safety and efficacy of pembrolizumab and trastuzumab in patients with<br \/>\n        trastuzumab-resistant HER2-positive metastatic breast cancer: Results<br \/>\n        from the PANACEA (IBCSG 45-13\/BIG 4-13\/KEYNOTE-014) study. Loi S.<br \/>\n        Wednesday, Dec. 6. 4:30 p.m. CT. Location: Hall 3.<\/i>\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract #PD6-13 Spotlight Session:<\/i> <i>Phase 1b\/2 study to<br \/>\n        evaluate eribulin mesylate in combination with pembrolizumab in<br \/>\n        patients with metastatic triple-negative breast cancer. Tolaney SM.<br \/>\n        Thursday, Dec. 7. 5:00 p.m. \u2013 7:00 p.m. CT. Location: Stars at Night<br \/>\n        Ballroom 3 &amp; 4.<\/i>\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract #PD6-08 Spotlight Session: Analysis of immune infiltrates<br \/>\n        (assessed via multiplex fluorescence immunohistochemistry) and immune<br \/>\n        gene expression signatures as predictors of response to the checkpoint<br \/>\n        inhibitor pembrolizumab in the neoadjuvant I-SPY 2 trial.<\/i> <i>Campbell<br \/>\n        M. Thursday, Dec. 7. 5:00 p.m. \u2013 7:00 p.m. CT. Location: Stars at<br \/>\n        Night Ballroom 3 &amp; 4.<\/i>\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract #PD6-14 Spotlight Session: Analysis of DNA repair<br \/>\n        deficiency biomarkers as predictors of response to the PD1 inhibitor<br \/>\n        pembrolizumab: Results from the neoadjuvant I-SPY 2 TRIAL for Stage<br \/>\n        II-III high-risk breast cancer. Yau C. Thursday, Dec. 7. 5:00 p.m. \u2013<br \/>\n        7:00 p.m. CT. Location: Stars at Night Ballroom 3 &amp; 4.<\/i>\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract #P1-09-01 Poster Session: A phase 1b study of abemaciclib<br \/>\n        plus pembrolizumab for patients with hormone receptor-positive (HR+),<br \/>\n        human epidermal growth factor receptor 2-negative (HER2-) metastatic<br \/>\n        breast cancer (MBC). Rugo HS. Wednesday, Dec. 6. 5:00 p.m. \u2013 7:00 p.m.<br \/>\n        CT. Location: Hall 1.<\/i>\n      <\/li>\n<\/ul>\n<p>\n      The KEYTRUDA (pembrolizumab) breast cancer clinical development program<br \/>\n      encompasses 15 internal and external collaborative studies across<br \/>\n      multiple breast cancer subtypes including four registration-enabling<br \/>\n      studies in TNBC (KEYNOTE-119, KEYNOTE-355, KEYNOTE-242 and KEYNOTE-522),<br \/>\n      and 11 other studies evaluating KEYTRUDA either in monotherapy or in<br \/>\n      combination with other anti-cancer treatments.\n    <\/p>\n<p>\n      <b>About the AstraZeneca and Merck Strategic Oncology Collaboration<\/b>\n    <\/p>\n<p>\n      On July 27, 2017, AstraZeneca and Merck, announced a global strategic<br \/>\n      oncology collaboration to co-develop and co-commercialize AstraZeneca\u2019s<br \/>\n      LYNPARZA (olaparib), the world\u2019s first PARP inhibitor, and potential new<br \/>\n      medicine selumetinib, a MEK inhibitor, for multiple cancer types. The<br \/>\n      collaboration is based on increasing evidence that PARP and MEK<br \/>\n      inhibitors can be combined with PD-L1\/PD-1 inhibitors for a range of<br \/>\n      tumor types. Working together, the companies will jointly develop<br \/>\n      LYNPARZA and selumetinib in combination with other potential new<br \/>\n      medicines and as a monotherapy. Independently, the companies will<br \/>\n      develop LYNPARZA and selumetinib in combination with their respective<br \/>\n      PD-L1 and PD-1 medicines.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae&nbsp;<\/b><br \/>\n<\/sup><br \/>\n<b>(pembrolizumab)<br \/>\n      Injection 100&nbsp;mg<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of<br \/>\n      the body\u2019s immune system to help detect and fight tumor cells. KEYTRUDA<br \/>\n      (pembrolizumab) is a humanized monoclonal antibody that blocks the<br \/>\n      interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby<br \/>\n      activating T lymphocytes which may affect both tumor cells and healthy<br \/>\n      cells.\n    <\/p>\n<p>\n      Merck has the industry\u2019s largest immuno-oncology clinical research<br \/>\n      program, which currently involves more than 650 trials studying KEYTRUDA<br \/>\n      across a wide variety of cancers and treatment settings. The KEYTRUDA<br \/>\n      clinical program seeks to understand the role of KEYTRUDA across cancers<br \/>\n      and the factors that may predict a patient\u2019s likelihood of benefitting<br \/>\n      from treatment with KEYTRUDA, including exploring several different<br \/>\n      biomarkers.\n    <\/p>\n<p>\n      <b>KEYTRUDA (pembrolizumab)&nbsp;Indications and Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma.at a fixed dose of 200 mg every three weeks until<br \/>\n      disease progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the first-line treatment<br \/>\n      of patients with metastatic non-small cell lung cancer (NSCLC) whose<br \/>\n      tumors have high PD-L1 expression [tumor proportion score (TPS) \u226550%] as<br \/>\n      determined by an FDA-approved test, with no EGFR or ALK genomic tumor<br \/>\n      aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is also indicated for the treatment of<br \/>\n      patients with metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as<br \/>\n      determined by an FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA, in combination with pemetrexed and carboplatin, is indicated<br \/>\n      for the first-line treatment of patients with metastatic nonsquamous<br \/>\n      NSCLC. This indication is approved under accelerated approval based on<br \/>\n      tumor response rate and progression-free survival. Continued approval<br \/>\n      for this indication may be contingent upon verification and description<br \/>\n      of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      When administering KEYTRUDA (pembrolizumab) in combination with<br \/>\n      chemotherapy, KEYTRUDA should be administered prior to chemotherapy when<br \/>\n      given on the same day. See also the Prescribing Information for<br \/>\n      pemetrexed and carboplatin.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Classical Hodgkin Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory classical Hodgkin lymphoma (cHL), or who have relapsed<br \/>\n      after three or more prior lines of therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. In adults with cHL, KEYTRUDA is administered at a<br \/>\n      fixed dose of 200 mg every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression. In pediatric patients with cHL, KEYTRUDA is administered at<br \/>\n      a dose of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression.\n    <\/p>\n<p>\n      <i>Urothelial Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma who are not eligible for<br \/>\n      cisplatin-containing chemotherapy. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and duration of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma who have disease progression<br \/>\n      during or following platinum-containing chemotherapy or within 12 months<br \/>\n      of neoadjuvant or adjuvant treatment with platinum-containing<br \/>\n      chemotherapy.\n    <\/p>\n<p>\n      In locally advanced or metastatic urothelial carcinoma, KEYTRUDA<br \/>\n      (pembrolizumab) is administered at a fixed dose of 200 mg every three<br \/>\n      weeks until disease progression or unacceptable toxicity, or up to 24<br \/>\n      months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Microsatellite Instability-High (MSI-H) Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with unresectable or metastatic microsatellite instability-high (MSI-H)<br \/>\n      or mismatch repair deficient (dMMR)\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        solid tumors that have progressed following prior treatment and who<br \/>\n        have no satisfactory alternative treatment options, or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        colorectal cancer that has progressed following treatment with<br \/>\n        fluoropyrimidine, oxaliplatin, and irinotecan.\n      <\/li>\n<\/ul>\n<p>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The safety and<br \/>\n      effectiveness of KEYTRUDA in pediatric patients with MSI-H central<br \/>\n      nervous system cancers have not been established.\n    <\/p>\n<p>\n      In adult patients with MSI-H cancer, KEYTRUDA is administered at a fixed<br \/>\n      dose of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression. In<br \/>\n      children with MSI-H cancer, KEYTRUDA is administered at a dose of 2<br \/>\n      mg\/kg (up to a maximum of 200 mg) every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Gastric Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent<br \/>\n      locally advanced or metastatic gastric or gastroesophageal junction<br \/>\n      (GEJ) adenocarcinoma whose tumors express PD-L1 [Combined Positive Score<br \/>\n      (CPS) \u22651] as determined by an FDA-approved test, with disease<br \/>\n      progression on or after two or more prior lines of therapy including<br \/>\n      fluoropyrimidine- and platinum-containing chemotherapy and if<br \/>\n      appropriate, HER2\/neu-targeted therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. The recommended dose of KEYTRUDA is 200 mg every<br \/>\n      three weeks until disease progression, unacceptable toxicity, or up to<br \/>\n      24 months in patients without disease progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>&nbsp;<b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 94 (3.4%) of 2799 patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%)<br \/>\n      pneumonitis, and occurred more frequently in patients with a history of<br \/>\n      prior thoracic radiation (6.9%) compared to those without (2.9%).<br \/>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or<br \/>\n      recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 48<br \/>\n      (1.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%) colitis. Monitor patients for signs and symptoms<br \/>\n      of colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 19<br \/>\n      (0.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%) hepatitis. Monitor patients for changes in liver<br \/>\n      function. Administer corticosteroids for Grade 2 or greater hepatitis<br \/>\n      and, based on severity of liver enzyme elevations, withhold or<br \/>\n      discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis. Hypophysitis occurred in 17 (0.6%) of<br \/>\n      2799 patients receiving KEYTRUDA, including Grade 2 (0.2%), 3 (0.3%),<br \/>\n      and 4 (&lt;0.1%) hypophysitis. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause thyroid disorders, including hyperthyroidism,<br \/>\n      hypothyroidism, and thyroiditis. Hyperthyroidism occurred in 96 (3.4%)<br \/>\n      of 2799 patients receiving KEYTRUDA, including Grade 2 (0.8%) and 3<br \/>\n      (0.1%) hyperthyroidism. Hypothyroidism occurred in 237 (8.5%) of 2799<br \/>\n      patients receiving KEYTRUDA, including Grade 2 (6.2%) and 3 (0.1%)<br \/>\n      hypothyroidism. The incidence of new or worsening hypothyroidism was<br \/>\n      higher in patients with HNSCC, occurring in 28 (15%) of 192 patients<br \/>\n      with HNSCC, including Grade 3 (0.5%) hypothyroidism. Thyroiditis<br \/>\n      occurred in 16 (0.6%) of 2799 patients receiving KEYTRUDA, including<br \/>\n      Grade 2 (0.3%) thyroiditis. Monitor patients for changes in thyroid<br \/>\n      function (at the start of treatment, periodically during treatment, and<br \/>\n      as indicated based on clinical evaluation) and for clinical signs and<br \/>\n      symptoms of thyroid disorders. Administer replacement hormones for<br \/>\n      hypothyroidism and manage hyperthyroidism with thionamides and<br \/>\n      beta-blockers as appropriate. Withhold or discontinue KEYTRUDA<br \/>\n      (pembrolizumab) for Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      KEYTRUDA can cause type 1 diabetes mellitus, including diabetic<br \/>\n      ketoacidosis, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for hyperglycemia or other signs and symptoms of<br \/>\n      diabetes. Administer insulin for type 1 diabetes, and withhold KEYTRUDA<br \/>\n      and administer antihyperglycemics in patients with severe hyperglycemia.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 9<br \/>\n      (0.3%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Monitor patients for changes in renal<br \/>\n      function. Administer corticosteroids for Grade 2 or greater nephritis.<br \/>\n      Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Immune-mediated rashes, including Stevens-Johnson syndrome (SJS), toxic<br \/>\n      epidermal necrolysis (TEN) (some cases with fatal outcome), exfoliative<br \/>\n      dermatitis, and bullous pemphigoid, can occur. Monitor patients for<br \/>\n      suspected severe skin reactions and based on the severity of the adverse<br \/>\n      reaction, withhold or permanently discontinue KEYTRUDA and administer<br \/>\n      corticosteroids. For signs or symptoms of SJS or TEN, withhold KEYTRUDA<br \/>\n      and refer the patient for specialized care for assessment and treatment.<br \/>\n      If SJS or TEN is confirmed, permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause other clinically important immune-mediated adverse<br \/>\n      reactions. These immune-mediated reactions may occur in any organ<br \/>\n      system. For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement to Grade 1 or less, initiate<br \/>\n      corticosteroid taper and continue to taper over at least 1 month. Based<br \/>\n      on limited data from clinical studies in patients whose immune-related<br \/>\n      adverse reactions could not be controlled with corticosteroid use,<br \/>\n      administration of other systemic immunosuppressants can be considered.<br \/>\n      Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less<br \/>\n      following corticosteroid taper. Permanently discontinue KEYTRUDA for any<br \/>\n      Grade 3 immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia<br \/>\n      gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures<br \/>\n      arising in a patient with inflammatory foci in brain parenchyma. In<br \/>\n      addition, myelitis and myocarditis were reported in other clinical<br \/>\n      trials, including classical Hodgkin lymphoma, and postmarketing use.\n    <\/p>\n<p>\n      Solid organ transplant rejection has been reported in postmarketing use<br \/>\n      of KEYTRUDA (pembrolizumab). Treatment with KEYTRUDA may increase the<br \/>\n      risk of rejection in solid organ transplant recipients. Consider the<br \/>\n      benefit of treatment with KEYTRUDA vs the risk of possible organ<br \/>\n      rejection in these patients.\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, including hypersensitivity and anaphylaxis, which have been<br \/>\n      reported in 6 (0.2%) of 2799 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions, including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Immune-mediated complications, including fatal events, occurred in<br \/>\n      patients who underwent allogeneic hematopoietic stem cell<br \/>\n      transplantation (HSCT) after being treated with KEYTRUDA. Of 23 patients<br \/>\n      with cHL who proceeded to allogeneic HSCT after treatment with KEYTRUDA<br \/>\n      on any trial, 6 patients (26%) developed graft-versus-host disease<br \/>\n      (GVHD), one of which was fatal, and 2 patients (9%) developed severe<br \/>\n      hepatic veno-occlusive disease (VOD) after reduced-intensity<br \/>\n      conditioning, one of which was fatal. Cases of fatal hyperacute GVHD<br \/>\n      after allogeneic HSCT have also been reported in patients with lymphoma<br \/>\n      who received a PD-1 receptor\u2013blocking antibody before transplantation.<br \/>\n      These complications may occur despite intervening therapy between PD-1<br \/>\n      blockade and allogeneic HSCT. Follow patients closely for early evidence<br \/>\n      of transplant-related complications such as hyperacute GVHD, severe<br \/>\n      (Grade 3 to 4) acute GVHD, steroid-requiring febrile syndrome, hepatic<br \/>\n      VOD, and other immune-mediated adverse reactions, and intervene promptly.\n    <\/p>\n<p>\n      In clinical trials in patients with multiple myeloma, the addition of<br \/>\n      KEYTRUDA to a thalidomide analogue plus dexamethasone resulted in<br \/>\n      increased mortality. Treatment of these patients with a PD-1 or PD-L1<br \/>\n      blocking antibody in this combination is not recommended outside of<br \/>\n      controlled clinical trials.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-006, KEYTRUDA (pembrolizumab) was discontinued due to adverse<br \/>\n      reactions in 9% of 555 patients with advanced melanoma; adverse<br \/>\n      reactions leading to discontinuation in more than one patient were<br \/>\n      colitis (1.4%), autoimmune hepatitis (0.7%), allergic reaction (0.4%),<br \/>\n      polyneuropathy (0.4%), and cardiac failure (0.4%). Adverse reactions<br \/>\n      leading to interruption of KEYTRUDA occurred in 21% of patients; the<br \/>\n      most common (\u22651%) was diarrhea (2.5%). The most common adverse reactions<br \/>\n      with KEYTRUDA vs ipilimumab were fatigue (28% vs 28%), diarrhea (26%<br \/>\n      with KEYTRUDA), rash (24% vs 23%), and nausea (21% with KEYTRUDA).<br \/>\n      Corresponding incidence rates are listed for ipilimumab only for those<br \/>\n      adverse reactions that occurred at the same or lower rate than with<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-010, KEYTRUDA monotherapy was discontinued due to adverse<br \/>\n      reactions in 8% of 682 patients with metastatic NSCLC. The most common<br \/>\n      adverse event resulting in permanent discontinuation of KEYTRUDA was<br \/>\n      pneumonitis (1.8%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA occurred in 23% of patients; the most common (\u22651%) were<br \/>\n      diarrhea (1%), fatigue (1.3%), pneumonia (1%), liver enzyme elevation<br \/>\n      (1.2%), decreased appetite (1.3%), and pneumonitis (1%). The most common<br \/>\n      adverse reactions (occurring in at least 20% of patients and at a higher<br \/>\n      incidence than with docetaxel) were decreased appetite (25% vs 23%),<br \/>\n      dyspnea (23% vs 20%), and nausea (20% vs 18%).\n    <\/p>\n<p>\n      In KEYNOTE-021(G1), when KEYTRUDA was administered in combination with<br \/>\n      carboplatin and pemetrexed (carbo\/pem) in advanced nonsquamous NSCLC,<br \/>\n      KEYTRUDA was discontinued in 10% of 59 patients. The most common adverse<br \/>\n      reaction resulting in discontinuation of KEYTRUDA (\u22652%) was acute kidney<br \/>\n      injury (3.4%). Adverse reactions leading to interruption of KEYTRUDA<br \/>\n      occurred in 39% of patients; the most common (\u22652%) were fatigue (8%),<br \/>\n      neutrophil count decreased (8%), anemia (5%), dyspnea (3.4%), and<br \/>\n      pneumonitis (3.4%).The most common adverse reactions (\u226520%) with<br \/>\n      KEYTRUDA compared to carbo\/pem alone were fatigue (71% vs 50%), nausea<br \/>\n      (68% vs 56%), constipation (51% vs 37%), rash (42% vs 21%), vomiting<br \/>\n      (39% vs 27%), dyspnea (39% vs 21%), diarrhea (37% vs 23%), decreased<br \/>\n      appetite (31% vs 23%), headache (31% vs 16%), cough (24% vs 18%),<br \/>\n      dizziness (24% vs 16%), insomnia (24% vs 15%), pruritus (24% vs 4.8%),<br \/>\n      peripheral edema (22% vs 18%), dysgeusia (20% vs 11%), alopecia (20% vs<br \/>\n      3.2%), upper respiratory tract infection (20% vs 3.2%), and arthralgia<br \/>\n      (15% vs 24%). This study was not designed to demonstrate a statistically<br \/>\n      significant difference in adverse reaction rates for KEYTRUDA as<br \/>\n      compared to carbo\/pem alone for any specified adverse reaction.\n    <\/p>\n<p>\n      In KEYNOTE-012, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      17% of 192 patients with HNSCC. Serious adverse reactions occurred in<br \/>\n      45% of patients. The most frequent serious adverse reactions reported in<br \/>\n      at least 2% of patients were pneumonia, dyspnea, confusional state,<br \/>\n      vomiting, pleural effusion, and respiratory failure. The most common<br \/>\n      adverse reactions (reported in at least 20% of patients) were fatigue,<br \/>\n      decreased appetite, and dyspnea. Adverse reactions occurring in patients<br \/>\n      with HNSCC were generally similar to those occurring in patients with<br \/>\n      melanoma or NSCLC, with the exception of increased incidences of facial<br \/>\n      edema (10% all Grades; 2.1% Grades 3 or 4) and new or worsening<br \/>\n      hypothyroidism.\n    <\/p>\n<p>\n      In KEYNOTE-087, KEYTRUDA (pembrolizumab) was discontinued due to adverse<br \/>\n      reactions in 5% of 210 patients with cHL, and treatment was interrupted<br \/>\n      due to adverse reactions in 26% of patients. Fifteen percent (15%) of<br \/>\n      patients had an adverse reaction requiring systemic corticosteroid<br \/>\n      therapy. Serious adverse reactions occurred in 16% of patients. The most<br \/>\n      frequent serious adverse reactions (\u22651%) included pneumonia,<br \/>\n      pneumonitis, pyrexia, dyspnea, GVHD, and herpes zoster. Two patients<br \/>\n      died from causes other than disease progression; one from GVHD after<br \/>\n      subsequent allogeneic HSCT and one from septic shock. The most common<br \/>\n      adverse reactions (occurring in \u226520% of patients) were fatigue (26%),<br \/>\n      pyrexia (24%), cough (24%), musculoskeletal pain (21%), diarrhea (20%),<br \/>\n      and rash (20%).\n    <\/p>\n<p>\n      In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      11% of 370 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reactions (in \u226520% of patients) were<br \/>\n      fatigue (38%), musculoskeletal pain (24%), decreased appetite (22%),<br \/>\n      constipation (21%), rash (21%), and diarrhea (20%). Eighteen patients<br \/>\n      (5%) died from causes other than disease progression. Five patients<br \/>\n      (1.4%) who were treated with KEYTRUDA experienced sepsis which led to<br \/>\n      death, and 3 patients (0.8%) experienced pneumonia which led to death.<br \/>\n      Adverse reactions leading to interruption of KEYTRUDA occurred in 22% of<br \/>\n      patients; the most common (\u22651%) were liver enzyme increase, diarrhea,<br \/>\n      urinary tract infection, acute kidney injury, fatigue, joint pain, and<br \/>\n      pneumonia. Serious adverse reactions occurred in 42% of patients, the<br \/>\n      most frequent (\u22652%) of which were urinary tract infection, hematuria,<br \/>\n      acute kidney injury, pneumonia, and urosepsis.\n    <\/p>\n<p>\n      In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 266 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reaction resulting in permanent<br \/>\n      discontinuation of KEYTRUDA was pneumonitis (1.9%). Adverse reactions<br \/>\n      leading to interruption of KEYTRUDA occurred in 20% of patients; the<br \/>\n      most common (\u22651%) were urinary tract infection (1.5%), diarrhea (1.5%),<br \/>\n      and colitis (1.1%). The most common adverse reactions (\u226520%) in patients<br \/>\n      who received KEYTRUDA vs those who received chemotherapy were fatigue<br \/>\n      (38% vs 56%), musculoskeletal pain (32% vs 27%), pruritus (23% vs 6%),<br \/>\n      decreased appetite (21% vs 21%), nausea (21% vs 29%), and rash (20% vs<br \/>\n      13%). Serious adverse reactions occurred in 39% of KEYTRUDA-treated<br \/>\n      patients, the most frequent (\u22652%) of which were urinary tract infection,<br \/>\n      pneumonia, anemia, and pneumonitis.\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA (pembrolizumab) is excreted in human<br \/>\n      milk. Because many drugs are excreted in human milk, instruct women to<br \/>\n      discontinue nursing during treatment with KEYTRUDA and for 4 months<br \/>\n      after the final dose.\n    <\/p>\n<p>\n      There is limited experience in pediatric patients. In a study, 40<br \/>\n      pediatric patients (16 children aged 2 years to younger than 12 years<br \/>\n      and 24 adolescents aged 12 years to 18 years) with advanced melanoma,<br \/>\n      lymphoma, or PD-L1\u2013positive advanced, relapsed, or refractory solid<br \/>\n      tumors were administered KEYTRUDA 2 mg\/kg every 3 weeks. Patients<br \/>\n      received KEYTRUDA for a median of 3 doses (range 1\u201317 doses), with 34<br \/>\n      patients (85%) receiving KEYTRUDA for 2 doses or more. The safety<br \/>\n      profile in these pediatric patients was similar to that seen in adults<br \/>\n      treated with KEYTRUDA. Toxicities that occurred at a higher rate (\u226515%<br \/>\n      difference) in these patients when compared to adults under 65 years of<br \/>\n      age were fatigue (45%), vomiting (38%), abdominal pain (28%),<br \/>\n      hypertransaminasemia (28%), and hyponatremia (18%).\n    <\/p>\n<p>\n      <b>About LYNPARZA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (olaparib)<\/b>\n    <\/p>\n<p>\n      LYNPARZA was the first FDA-approved oral poly ADP-ribose polymerase<br \/>\n      (PARP) inhibitor that may exploit tumor DNA damage response (DDR)<br \/>\n      pathway deficiencies to potentially kill cancer cells. Specifically, in<br \/>\n      vitro studies have shown that olaparib-induced cytotoxicity may involve<br \/>\n      inhibition of PARP enzymatic activity and increased formation of<br \/>\n      PARP-DNA complexes, resulting in DNA damage and cancer cell death.\n    <\/p>\n<p>\n      <b>IMPORTANT SAFETY INFORMATION FOR LYNPARZA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae <\/b><br \/>\n<\/sup><br \/>\n<b>(olaparib)<\/b>\n    <\/p>\n<p>\n      <b>DOSING AND ADMINISTRATION<\/b>\n    <\/p>\n<p>\n      To avoid substitution errors and overdose, <b>do not substitute LYNPARZA<br \/>\n      tablets with LYNPARZA capsules <\/b>on a milligram-to-milligram basis due<br \/>\n      to differences in the dosing and bioavailability of each formulation.<br \/>\n      Recommended tablet dose is 300 mg, taken orally twice daily, with or<br \/>\n      without food. Continue treatment until disease progression or<br \/>\n      unacceptable toxicity. For adverse reactions, consider dose interruption<br \/>\n      or dose reduction.\n    <\/p>\n<p>\n      <b>WARNINGS AND PRECAUTIONS<\/b>\n    <\/p>\n<p>\n      There are no contraindications for LYNPARZA.\n    <\/p>\n<p>\n      <b>Myelodysplastic Syndrome\/Acute Myeloid Leukemia (MDS\/AML):&nbsp;<\/b>Occurred<br \/>\n      in &lt;1.5% of patients exposed to LYNPARZA (olaparib) monotherapy, and the<br \/>\n      majority of events had a fatal outcome. The duration of therapy in<br \/>\n      patients who developed secondary MDS\/AML varied from &lt;6 months to &gt;2<br \/>\n      years. All of these patients had previous chemotherapy with platinum<br \/>\n      agents and\/or other DNA-damaging agents, including radiotherapy, and<br \/>\n      some of these patients also had a history of previous cancer or bone<br \/>\n      marrow dysplasia.\n    <\/p>\n<p>\n      Do not start LYNPARZA until patients have recovered from hematological<br \/>\n      toxicity caused by previous chemotherapy (\u2264Grade 1). Monitor complete<br \/>\n      blood counts for cytopenia at baseline and monthly thereafter for<br \/>\n      clinically significant changes during treatment. For prolonged<br \/>\n      hematological toxicities, interrupt LYNPARZA and monitor blood counts<br \/>\n      weekly until recovery. If the levels have not recovered to Grade 1 or<br \/>\n      less after 4 weeks, refer the patient to a hematologist for further<br \/>\n      investigations, including bone marrow analysis and blood sample for<br \/>\n      cytogenetics. Discontinue LYNPARZA if MDS\/AML is confirmed.\n    <\/p>\n<p>\n      <b>Pneumonitis:<\/b>&nbsp;Occurred in &lt;1% of patients exposed to LYNPARZA, and<br \/>\n      some cases were fatal. If patients present with new or worsening<br \/>\n      respiratory symptoms such as dyspnea, cough, and fever, or a<br \/>\n      radiological abnormality occurs, interrupt treatment with LYNPARZA and<br \/>\n      initiate prompt investigation. Discontinue LYNPARZA if pneumonitis is<br \/>\n      confirmed and treat patient appropriately.\n    <\/p>\n<p>\n      <b>Embryo-Fetal Toxicity:<\/b>&nbsp;Based on its mechanism of action and<br \/>\n      findings in animals, LYNPARZA can cause fetal harm. A pregnancy test is<br \/>\n      recommended for females of reproductive potential prior to initiating<br \/>\n      treatment. Advise females of reproductive potential of the potential<br \/>\n      risk to a fetus and to use effective contraception during treatment and<br \/>\n      for 6 months after receiving the final dose.\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014Maintenance Setting<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>maintenance setting&nbsp;<\/b>for&nbsp;<b>SOLO-2<\/b>:&nbsp;nausea<br \/>\n      (76%), fatigue (including asthenia) (66%), anemia (44%), vomiting (37%),<br \/>\n      nasopharyngitis\/upper respiratory tract infection (URI)\/influenza (36%),<br \/>\n      diarrhea (33%), arthralgia\/myalgia (30%), dysgeusia (27%), headache<br \/>\n      (26%), decreased appetite (22%), and stomatitis (20%).\n    <\/p>\n<p>\n      <b>Study 19:<\/b> nausea (71%), fatigue (including asthenia) (63%),<br \/>\n      vomiting (35%), diarrhea (28%), anemia (23%), respiratory tract<br \/>\n      infection (22%), constipation (22%), headache (21%), and decreased<br \/>\n      appetite (21%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA (olaparib) in the&nbsp;<b>maintenance<br \/>\n      setting (SOLO-2\/Study 19<\/b>) were: increase in mean corpuscular volume<br \/>\n      (89%\/82%), decrease in hemoglobin (83%\/82%), decrease in leukocytes<br \/>\n      (69%\/58%), decrease in lymphocytes (67%\/52%), decrease in absolute<br \/>\n      neutrophil count (51%\/47%), increase in serum creatinine (44%\/45%), and<br \/>\n      decrease in platelets (42%\/36%).\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014Advanced g<i>BRCA<\/i>m ovarian cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      clinical trials of LYNPARZA for <b>advanced g<i>BRCA<\/i>m ovarian cancer<br \/>\n      after 3 or more lines of chemotherapy<\/b> (pooled from 6 studies) were:<br \/>\n      fatigue (including asthenia) (66%), nausea (64%), vomiting (43%), anemia<br \/>\n      (34%), diarrhea (31%), nasopharyngitis\/upper respiratory tract infection<br \/>\n      (URI) (26%), dyspepsia (25%), myalgia (22%), decreased appetite (22%),<br \/>\n      and arthralgia\/musculoskeletal pain (21%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA for <b>advanced g<i>BRCA<\/i>m ovarian cancer<br \/>\n      after 3 or more lines of chemotherapy<\/b> (pooled from 6 studies) were:<br \/>\n      decrease in hemoglobin (90%), increase in mean corpuscular volume (57%),<br \/>\n      decrease in lymphocytes (56%), increase in serum creatinine (30%),<br \/>\n      decrease in platelets (30%), and decrease in absolute neutrophil count<br \/>\n      (25%).\n    <\/p>\n<p>\n      <b>DRUG INTERACTIONS<\/b>\n    <\/p>\n<p>\n      <b>Anticancer Agents:<\/b>&nbsp;Clinical studies of LYNPARZA in combination<br \/>\n      with other myelosuppressive anticancer agents, including DNA-damaging<br \/>\n      agents, indicate a potentiation and prolongation of myelosuppressive<br \/>\n      toxicity.\n    <\/p>\n<p>\n      <b>CYP3A Inhibitors:<\/b>&nbsp;Avoid concomitant use of strong or moderate<br \/>\n      CYP3A inhibitors. If a strong or moderate CYP3A inhibitor must<br \/>\n      be&nbsp;co-administered, reduce the dose of LYNPARZA. Advise patients to<br \/>\n      avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange<br \/>\n      juice during LYNPARZA treatment.\n    <\/p>\n<p>\n      <b>CYP3A Inducers:<\/b>&nbsp;Avoid concomitant use of strong or moderate CYP3A<br \/>\n      inducers when using LYNPARZA. If a moderate inducer cannot be avoided,<br \/>\n      be aware of a potential for decreased efficacy of LYNPARZA.\n    <\/p>\n<p>\n      <b>USE IN SPECIFIC POPULATIONS<\/b>\n    <\/p>\n<p>\n      <b>Pediatric Use:<\/b> The safety and efficacy of LYNPARZA (olaparib)<br \/>\n      have not been established in pediatric patients.\n    <\/p>\n<p>\n      <b>Lactation:<\/b>&nbsp;No data are available regarding the presence of<br \/>\n      olaparib in human milk, the effects on the breastfed infant, or the<br \/>\n      effects on milk production. Because of the potential for serious adverse<br \/>\n      reactions in the breastfed infant, advise a lactating woman not to<br \/>\n      breastfeed during treatment with LYNPARZA and for 1 month after<br \/>\n      receiving the final dose.\n    <\/p>\n<p>\n      <b>Hepatic Impairment:<\/b>&nbsp;No adjustment to the starting dose is<br \/>\n      required in patients with mild hepatic impairment (Child-Pugh<br \/>\n      classification A). There are no data in patients with moderate or severe<br \/>\n      hepatic impairment.\n    <\/p>\n<p>\n      <b>Renal Impairment:<\/b>&nbsp;No adjustment to the starting dose is necessary<br \/>\n      in patients with mild renal impairment&nbsp;(CLcr 51-80 mL\/min).&nbsp;In patients<br \/>\n      with moderate renal impairment&nbsp;(CLcr 31-50 mL\/min),&nbsp;reduce the dose to<br \/>\n      200 mg twice daily. There are no data in patients with severe renal<br \/>\n      impairment or&nbsp;end-stage&nbsp;renal disease&nbsp;(CLcr \u226430 mL\/min).\n    <\/p>\n<p>\n      <b>APPROVED USES for LYNPARZA (olaparib)<\/b>\n    <\/p>\n<p>\n      LYNPARZA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        For the maintenance treatment of adult patients with recurrent<br \/>\n        epithelial ovarian, fallopian tube, or primary peritoneal cancer, who<br \/>\n        are in complete or partial response to platinum-based chemotherapy\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        For the treatment of adult patients with deleterious or suspected<br \/>\n        deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who<br \/>\n        have been treated with 3 or more prior lines of chemotherapy. Select<br \/>\n        patients for therapy based on an FDA-approved companion diagnostic for<br \/>\n        LYNPARZA\n      <\/li>\n<\/ul>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, helping people<br \/>\n      fight cancer is our passion and supporting accessibility to our cancer<br \/>\n      medicines is our commitment. Our focus is on pursuing research in<br \/>\n      immuno-oncology and we are accelerating every step in the journey \u2013 from<br \/>\n      lab to clinic \u2013 to potentially bring new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program evaluating our anti-PD-1 therapy across more than 30<br \/>\n      tumor types. We also continue to strengthen our immuno-oncology<br \/>\n      portfolio through strategic acquisitions and are prioritizing the<br \/>\n      development of several promising immunotherapeutic candidates with the<br \/>\n      potential to improve the treatment of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51723054&amp;newsitemid=20171130005484&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=2&amp;md5=459a5d2a3b6ed75820e3693ee6b3f279\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51723054&amp;newsitemid=20171130005484&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=9e90631d15e3f01f36a25b8a2ff3d9df\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a>&nbsp;and&nbsp;connect<br \/>\n      with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Ftwitter.com%2Fmerck&amp;esheet=51723054&amp;newsitemid=20171130005484&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=f6d07f4570ff11187d60fd241b8ea341\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2Fmerckinvents&amp;esheet=51723054&amp;newsitemid=20171130005484&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=ddfd354e749c7cfe58183738603a6a63\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.instagram.com%2Fmerck&amp;esheet=51723054&amp;newsitemid=20171130005484&amp;lan=en-US&amp;anchor=Instagram&amp;index=6&amp;md5=e4b61785a48e472496dc693eb12d62f1\" rel=\"nofollow\">Instagram<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51723054&amp;newsitemid=20171130005484&amp;lan=en-US&amp;anchor=YouTube&amp;index=7&amp;md5=fe012d07d038d036bd58f01d90375ad8\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51723054&amp;newsitemid=20171130005484&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=8&amp;md5=666bd7b799e69968a4cfe14251b8446f\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51723054&amp;newsitemid=20171130005484&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=9&amp;md5=6568fb07f29bf7ed0643875b4a0f2db5\" rel=\"nofollow\"><br \/>\n<span class=\"bwuline\">www.sec.gov<\/span><br \/>\n<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n      <i>###<\/i>\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51723054&amp;newsitemid=20171130005484&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=10&amp;md5=22f070e5be536c5748c5e006ebc0b8cc\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b><br \/>\n      and Patient Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51723054&amp;newsitemid=20171130005484&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=11&amp;md5=f0242f03bc7805e6848d78c597fab9f3\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n      <b>Please see complete&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.azpicentral.com%2Flynparza_tb%2Fpi_lynparza_tb.pdf%23page%3D1&amp;esheet=51723054&amp;newsitemid=20171130005484&amp;lan=en-US&amp;anchor=Prescribing+Information&amp;index=12&amp;md5=a9bb83129181f2c7056989a15986dd6f\" rel=\"nofollow\"><br \/>\n<b>Prescribing<br \/>\n      Information<\/b><br \/>\n<\/a><br \/>\n<b> for LYNPARZA, including Patient Information<br \/>\n      (Medication Guide)<\/b>\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20171130005484r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck <br \/> <span>Media:<\/span> <br \/>Pamela        Eisele, 267-305-3558<br \/>or<br \/>Ann Bush, 908-740-6677<br \/>or<br \/> <span>Investors:<\/span> <br \/>Teri        Loxam, 908-740-1986<br \/>or<br \/>Michael DeCarbo, 908-740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Efficacy Data from Phase 2 KEYNOTE-086 Trial, Cohort B, for KEYTRUDA Monotherapy in Patients with Untreated Metastatic Triple-Negative Breast Cancer to Be Featured in Spotlight Session Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new and updated data from six abstracts investigating KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, as both monotherapy and combination therapy, across a range of difficult-to-treat breast cancers, will be presented at the 2017 San Antonio Breast Cancer Symposium (SABCS), Dec. 5 \u2013 9. In addition to the presentation of KEYTRUDA data at SABCS, updated data on LYNPARZA\u00ae (olaparib), the first-in-class poly ADP-ribose polymerase (PARP) inhibitor being co-developed and co-commercialized with AstraZeneca, will be presented. KEYTRUDA presentations include a Spotlight Session with findings from the phase 2 KEYNOTE-086 trial, Cohort B, investigating KEYTRUDA as a monotherapy in previously untreated patients<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,289],"class_list":["post-745446","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New and Updated Data for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) and Updated Data on LYNPARZA\u00ae (olaparib) in Multiple Breast Cancer Subtypes to Be Presented at the 2017 San Antonio Breast Cancer Symposium (SABCS) - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-and-updated-data-for-mercks-keytruda-pembrolizumab-and-updated-data-on-lynparza-olaparib-in-multiple-breast-cancer-subtypes-to-be-presented-at-the-2017-san-antonio-breast\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New and Updated Data for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) and Updated Data on LYNPARZA\u00ae (olaparib) in Multiple Breast Cancer Subtypes to Be Presented at the 2017 San Antonio Breast Cancer Symposium (SABCS) - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Efficacy Data from Phase 2 KEYNOTE-086 Trial, Cohort B, for KEYTRUDA Monotherapy in Patients with Untreated Metastatic Triple-Negative Breast Cancer to Be Featured in Spotlight Session Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new and updated data from six abstracts investigating KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, as both monotherapy and combination therapy, across a range of difficult-to-treat breast cancers, will be presented at the 2017 San Antonio Breast Cancer Symposium (SABCS), Dec. 5 \u2013 9. In addition to the presentation of KEYTRUDA data at SABCS, updated data on LYNPARZA\u00ae (olaparib), the first-in-class poly ADP-ribose polymerase (PARP) inhibitor being co-developed and co-commercialized with AstraZeneca, will be presented. KEYTRUDA presentations include a Spotlight Session with findings from the phase 2 KEYNOTE-086 trial, Cohort B, investigating KEYTRUDA as a monotherapy in previously untreated patients\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-and-updated-data-for-mercks-keytruda-pembrolizumab-and-updated-data-on-lynparza-olaparib-in-multiple-breast-cancer-subtypes-to-be-presented-at-the-2017-san-antonio-breast\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"27 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-and-updated-data-for-mercks-keytruda-pembrolizumab-and-updated-data-on-lynparza-olaparib-in-multiple-breast-cancer-subtypes-to-be-presented-at-the-2017-san-antonio-breast\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-and-updated-data-for-mercks-keytruda-pembrolizumab-and-updated-data-on-lynparza-olaparib-in-multiple-breast-cancer-subtypes-to-be-presented-at-the-2017-san-antonio-breast\\\/\",\"name\":\"New and Updated Data for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) and Updated Data on LYNPARZA\u00ae (olaparib) in Multiple Breast Cancer Subtypes to Be Presented at the 2017 San Antonio Breast Cancer Symposium (SABCS) - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-11-30T07:00:00+00:00\",\"dateModified\":\"2025-11-07T06:26:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-and-updated-data-for-mercks-keytruda-pembrolizumab-and-updated-data-on-lynparza-olaparib-in-multiple-breast-cancer-subtypes-to-be-presented-at-the-2017-san-antonio-breast\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-and-updated-data-for-mercks-keytruda-pembrolizumab-and-updated-data-on-lynparza-olaparib-in-multiple-breast-cancer-subtypes-to-be-presented-at-the-2017-san-antonio-breast\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-and-updated-data-for-mercks-keytruda-pembrolizumab-and-updated-data-on-lynparza-olaparib-in-multiple-breast-cancer-subtypes-to-be-presented-at-the-2017-san-antonio-breast\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New and Updated Data for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) and Updated Data on LYNPARZA\u00ae (olaparib) in Multiple Breast Cancer Subtypes to Be Presented at the 2017 San Antonio Breast Cancer Symposium (SABCS)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New and Updated Data for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) and Updated Data on LYNPARZA\u00ae (olaparib) in Multiple Breast Cancer Subtypes to Be Presented at the 2017 San Antonio Breast Cancer Symposium (SABCS) - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-and-updated-data-for-mercks-keytruda-pembrolizumab-and-updated-data-on-lynparza-olaparib-in-multiple-breast-cancer-subtypes-to-be-presented-at-the-2017-san-antonio-breast\/","og_locale":"en_US","og_type":"article","og_title":"New and Updated Data for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) and Updated Data on LYNPARZA\u00ae (olaparib) in Multiple Breast Cancer Subtypes to Be Presented at the 2017 San Antonio Breast Cancer Symposium (SABCS) - Merck.com","og_description":"Efficacy Data from Phase 2 KEYNOTE-086 Trial, Cohort B, for KEYTRUDA Monotherapy in Patients with Untreated Metastatic Triple-Negative Breast Cancer to Be Featured in Spotlight Session Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new and updated data from six abstracts investigating KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, as both monotherapy and combination therapy, across a range of difficult-to-treat breast cancers, will be presented at the 2017 San Antonio Breast Cancer Symposium (SABCS), Dec. 5 \u2013 9. In addition to the presentation of KEYTRUDA data at SABCS, updated data on LYNPARZA\u00ae (olaparib), the first-in-class poly ADP-ribose polymerase (PARP) inhibitor being co-developed and co-commercialized with AstraZeneca, will be presented. KEYTRUDA presentations include a Spotlight Session with findings from the phase 2 KEYNOTE-086 trial, Cohort B, investigating KEYTRUDA as a monotherapy in previously untreated patients","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-and-updated-data-for-mercks-keytruda-pembrolizumab-and-updated-data-on-lynparza-olaparib-in-multiple-breast-cancer-subtypes-to-be-presented-at-the-2017-san-antonio-breast\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:07+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"27 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-and-updated-data-for-mercks-keytruda-pembrolizumab-and-updated-data-on-lynparza-olaparib-in-multiple-breast-cancer-subtypes-to-be-presented-at-the-2017-san-antonio-breast\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-and-updated-data-for-mercks-keytruda-pembrolizumab-and-updated-data-on-lynparza-olaparib-in-multiple-breast-cancer-subtypes-to-be-presented-at-the-2017-san-antonio-breast\/","name":"New and Updated Data for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) and Updated Data on LYNPARZA\u00ae (olaparib) in Multiple Breast Cancer Subtypes to Be Presented at the 2017 San Antonio Breast Cancer Symposium (SABCS) - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-11-30T07:00:00+00:00","dateModified":"2025-11-07T06:26:07+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-and-updated-data-for-mercks-keytruda-pembrolizumab-and-updated-data-on-lynparza-olaparib-in-multiple-breast-cancer-subtypes-to-be-presented-at-the-2017-san-antonio-breast\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-and-updated-data-for-mercks-keytruda-pembrolizumab-and-updated-data-on-lynparza-olaparib-in-multiple-breast-cancer-subtypes-to-be-presented-at-the-2017-san-antonio-breast\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-and-updated-data-for-mercks-keytruda-pembrolizumab-and-updated-data-on-lynparza-olaparib-in-multiple-breast-cancer-subtypes-to-be-presented-at-the-2017-san-antonio-breast\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"New and Updated Data for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) and Updated Data on LYNPARZA\u00ae (olaparib) in Multiple Breast Cancer Subtypes to Be Presented at the 2017 San Antonio Breast Cancer Symposium (SABCS)"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"5a69f84c-9401-4df0-90d1-3111d5b7f129","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/New-and-Updated-Data-for-Mercks-KEYTRUDA-pembrolizumab-and-Updated-Data-on-LYNPARZA-olaparib-in-Multiple-Breast-Cancer-Subtypes-to-Be-S88OK.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745446","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745446\/revisions"}],"predecessor-version":[{"id":3674823,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745446\/revisions\/3674823"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745446"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745446"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}